Overview of the Class Action Lawsuit against Capricor Therapeutics
Attention shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR)! If you purchased shares during the specified class period, this information is crucial for you. The Gross Law Firm has identified a pending class action that may affect your investments, and it’s important to understand the implications.
What is the Class Period?
The class period for this lawsuit encompasses transactions that occurred between October 9, 2024, and July 10, 2025. Shareholders who acquired shares during this timeframe are encouraged to take prompt action to protect their investment rights.
Possible Claims and Lead Plaintiff Appointment
Investors are encouraged to reach out to the firm if they wish to be considered for a lead plaintiff role. Being a lead plaintiff is not a prerequisite for participating in the potential recovery; however, it can strengthen the case.
Allegations Against Capricor
The heart of the allegations centers around misleading statements made by the company regarding its lead cell therapy candidate, deramiocel, intended for treating cardiomyopathy linked to Duchenne muscular dystrophy (DMD). This misinformation may have led investors to believe that the company would secure a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA).
Consequences of Recent FDA Response
On July 11, 2025, Capricor publicly acknowledged that it received a Complete Response Letter (CRL) from the FDA, which pointed out that the BLA did not meet the necessary statutory requirements for substantial evidence of effectiveness. Furthermore, the CRL highlighted that additional clinical data is required, which was a significant update for investors and caused a notable decline in share prices.
Impact on Share Price
Following the FDA news, Capricor's stock experienced a sharp decrease, plummeting from $11.40 per share on July 10, 2025, to $7.64 per share by the following day—reflecting investors’ reactions to the uncertainty surrounding the drug's approval.
Registration Deadline for Shareholders
Important to note, the deadline for shareholders wishing to register for this class action is September 15, 2025. It is vital not to delay; registering early could be key in participating in any recovery related to this lawsuit.
Next Steps for Investors
After registering as a shareholder affected by this situation, you will gain access to a portfolio monitoring service, allowing you to stay updated on the case’s status. Remember, there is no cost or obligation to participate, making it a risk-free opportunity to protect your investments.
Why Choose the Gross Law Firm?
The Gross Law Firm is recognized nationally for its commitment to protecting investor rights against deceitful business practices. Their mission is to hold companies accountable for making false statements and misleading investors, ensuring all affected shareholders have the opportunity to seek justice.
Contact Information
If you are interested in registering, you can reach out via email at dg@securitiesclasslaw.com. Alternatively, you can call the Gross Law Firm at (646) 453-8903. Ensure you provide all necessary information to proceed with your class action registration.
Frequently Asked Questions
What is the purpose of this class action lawsuit?
The class action aims to hold Capricor accountable for any misleading information provided to shareholders regarding its drug development and FDA approval processes.
How can I participate in the class action?
Shareholders need to register with the Gross Law Firm by the specified deadline to be part of the class action. This can often be done online or by contacting the firm directly.
What does it mean to be a lead plaintiff?
A lead plaintiff represents the interests of all class members in the lawsuit. While it is not mandatory to take this role, being a lead plaintiff can help in defining the direction of the case.
What might shareholders recover from this lawsuit?
Depending on the case's outcome, shareholders may recover financial losses stemming from the misleading statements about Capricor's product and its subsequent stock price decline.
Is there any cost to join the class action?
No, there is no cost to register or participate in the class action, making it an accessible option for affected shareholders.
